It’s easy to view the regulatory approval process as the finish line for your new Alzheimer’s therapy. But, beyond clinical safety and efficacy, you need to demonstrate your product’s value proposition to the organizations that facilitate patient access. This new white paper, authored by a group of experts at Worldwide Clinical Trials, discusses considerations and strategies for building a compelling commercial case for a novel Alzheimer’s therapy.
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
